A year-long immune profile of the systemic response in acute stroke survivors.
Aged
Aged, 80 and over
Brain Ischemia
/ complications
CREB-Binding Protein
/ metabolism
Cognition
/ physiology
Cognition Disorders
/ etiology
Cognitive Dysfunction
/ complications
Cohort Studies
Female
Humans
Immunoglobulin M
Longitudinal Studies
Male
Middle Aged
Neutrophils
STAT3 Transcription Factor
/ metabolism
Signal Transduction
Stroke
/ complications
Survivors
cognitive outcomes
machine learning
mass cytometry
stroke
systemic immunology
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
received:
11
08
2018
revised:
18
11
2018
accepted:
14
12
2018
pubmed:
13
3
2019
medline:
18
12
2019
entrez:
13
3
2019
Statut:
ppublish
Résumé
Stroke is a leading cause of cognitive impairment and dementia, but the mechanisms that underlie post-stroke cognitive decline are not well understood. Stroke produces profound local and systemic immune responses that engage all major innate and adaptive immune compartments. However, whether the systemic immune response to stroke contributes to long-term disability remains ill-defined. We used a single-cell mass cytometry approach to comprehensively and functionally characterize the systemic immune response to stroke in longitudinal blood samples from 24 patients over the course of 1 year and correlated the immune response with changes in cognitive functioning between 90 and 365 days post-stroke. Using elastic net regularized regression modelling, we identified key elements of a robust and prolonged systemic immune response to ischaemic stroke that occurs in three phases: an acute phase (Day 2) characterized by increased signal transducer and activator of transcription 3 (STAT3) signalling responses in innate immune cell types, an intermediate phase (Day 5) characterized by increased cAMP response element-binding protein (CREB) signalling responses in adaptive immune cell types, and a late phase (Day 90) by persistent elevation of neutrophils, and immunoglobulin M+ (IgM+) B cells. By Day 365 there was no detectable difference between these samples and those from an age- and gender-matched patient cohort without stroke. When regressed against the change in the Montreal Cognitive Assessment scores between Days 90 and 365 after stroke, the acute inflammatory phase Elastic Net model correlated with post-stroke cognitive trajectories (r = -0.692, Bonferroni-corrected P = 0.039). The results demonstrate the utility of a deep immune profiling approach with mass cytometry for the identification of clinically relevant immune correlates of long-term cognitive trajectories.
Identifiants
pubmed: 30860258
pii: 5373058
doi: 10.1093/brain/awz022
pmc: PMC6933508
doi:
Substances chimiques
Immunoglobulin M
0
STAT3 Transcription Factor
0
CREB-Binding Protein
EC 2.3.1.48
CREBBP protein, human
EC 2.3.1.48
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
978-991Subventions
Organisme : NIGMS NIH HHS
ID : K23 GM111657
Pays : United States
Informations de copyright
© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Références
J Immunol. 2010 Dec 1;185(11):6413-9
pubmed: 21084670
J Clin Invest. 2002 May;109(9):1143-8
pubmed: 11994402
J Leukoc Biol. 2010 May;87(5):779-89
pubmed: 20130219
Acta Neurol Scand. 2005 Jun;111(6):360-5
pubmed: 15876336
Biochem Biophys Res Commun. 2010 Nov 19;402(3):500-6
pubmed: 20965150
Stroke. 2007 Feb;38(2 Suppl):770-3
pubmed: 17261736
Lancet Neurol. 2017 Mar;16(3):217-226
pubmed: 28229893
Sci Transl Med. 2014 Sep 24;6(255):255ra131
pubmed: 25253674
PLoS One. 2013 Apr 23;8(4):e62101
pubmed: 23626774
Nat Med. 2011 Jul 07;17(7):796-808
pubmed: 21738161
Sci Immunol. 2017 Sep 1;2(15):null
pubmed: 28864494
Nat Rev Immunol. 2015 Aug;15(8):471-85
pubmed: 26160613
Stroke. 1996 Sep;27(9):1553-7
pubmed: 8784129
J Clin Invest. 2013 Apr;123(4):1580-9
pubmed: 23454751
Stroke. 2017 Jan;48(1):180-186
pubmed: 27899749
J Neuroimmunol. 2007 Mar;184(1-2):53-68
pubmed: 17188755
J Cereb Blood Flow Metab. 2005 Dec;25(12):1634-44
pubmed: 15931160
Bioinformatics. 2019 Jan 1;35(1):95-103
pubmed: 30561547
JAMA Neurol. 2017 Dec 1;74(12):1439-1445
pubmed: 29059266
Cytometry A. 2015 Feb;87(2):97-8
pubmed: 25614362
Nat Protoc. 2015 Feb;10(2):316-33
pubmed: 25612231
Cytometry A. 2014 Dec;85(12):1011-9
pubmed: 25274027
Nat Rev Neurol. 2012 Jun 05;8(7):401-10
pubmed: 22664787
J Neurol Sci. 1997 May 1;148(1):101-5
pubmed: 9125396
Annu Rev Immunol. 2018 Apr 26;36:783-812
pubmed: 29677475
Cytometry A. 2013 May;83(5):483-94
pubmed: 23512433
Acta Neuropathol. 2004 Dec;108(6):524-30
pubmed: 15517310
J Neurochem. 2012 Nov;123 Suppl 2:148-55
pubmed: 23050652
Immunity. 2018 Feb 20;48(2):380-395.e6
pubmed: 29426702
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Lancet Neurol. 2016 Jul;15(8):869-881
pubmed: 27180033
Stem Cells Dev. 2017 Jun 1;26(11):787-797
pubmed: 28323540
Brain Behav Immun. 2017 Aug;64:1-8
pubmed: 27531189
J Neurosci. 2015 Feb 4;35(5):2133-45
pubmed: 25653369
Neurology. 2012 Jun 5;78(23):1860-7
pubmed: 22573626
Stroke. 2004 Jun;35(6):1264-8
pubmed: 15118167
Cytometry B Clin Cytom. 2017 Jan;92(1):79-87
pubmed: 27933753
J Neurochem. 2012 Nov;123 Suppl 2:29-38
pubmed: 23050640
JAMA. 2015 Jul 7;314(1):41-51
pubmed: 26151265
Neurotherapeutics. 2016 Oct;13(4):671-684
pubmed: 27538777